The current study, as well as an earlier study that tested 21 IVIG lots (9 Gamunex C, 10 Gammagard Liquid, 2 other) with a SARS-CoV-2-specific enzyme-linked immunosorbent assay (ELISA; receptor-binding domain or spike protein) that was shown to correlate well with a neutralization test [14] revealed the absence of cross-reactive antibodies against SARS-CoV-2 in IVIG lots produced from prepandemic plasma. Currently available IVIGs can therefore not be expected to afford protection from SARS-CoV-2 infection. Nevertheless, several clinical trials currently investigate IVIG at high dosage in the treatment of COVID-19 patients (clinicaltrials.gov), with the expected benefit attributable to the anti-inflammatory and immunomodulatory capacity of IVIG, rather than an antiviral effect.